Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Novo Nordisk Launches GLAM™ (Great Life After Menopause) to Ignite the Conversation on Vaginal Health

      First-in-Kind Alliance Sets Out to Break Taboo Around "Silent Symptom" of Menopause

      Novo Nordisk

      News provided by

      Novo Nordisk

      Sep 09, 2013, 09:36 ET

      Share this article

      Share this article


      PLAINSBORO, N.J., Sept. 9, 2013 /PRNewswire/ -- As many as 75 percent of women who have gone through menopause are living with vaginal dryness, a bothersome symptom that they feel is negatively affecting their quality of life.[1,2] Despite the high prevalence, only 25 percent of women with vaginal dryness will take action to resolve it.[1] To address this, five leading women's health advocates today announced the formation of GLAM™ (Great Life After Menopause), an alliance that will encourage the millions of women whose lives are disrupted by this "silent symptom" of menopause to speak up and seek help.

      (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO )

      Geri Brin, founder of women's online destination FabOverFifty.com; Ellen Dolgen, founder of Menopause Mondays and author of Shmirshky: The Pursuit of Hormone Happiness; Karen Giblin, president and founder of Red Hot Mamas menopause education programs; Barbara Hannah Grufferman, author of The Best of Everything After 50; and Staness Jonekos, author of The Menopause Makeover: The Ultimate Guide to Taking Control of Your Health and Beauty During Menopause will raise awareness of the vaginal changes associated with menopause and educate women that these changes are due to a chronic, treatable condition.

      Renowned menopause specialist, Mary Jane Minkin, MD, FACOG, NCMP, clinical professor of obstetrics and gynecology at Yale University School of Medicine, will serve as the group's medical consultant.

      Vaginal dryness, along with other vaginal symptoms – like vaginal irritation, itching in and around the vagina, pain and bleeding during intercourse, vaginal soreness, and pain or bleeding during urination – are most commonly caused by the vaginal changes that occur before and after menopause due to diminishing levels of estrogen.[1] These changes are collectively referred to as vaginal atrophy.[1]

      "Women tend to shy away from talking about things like vaginal and sexual health," says Dr. Minkin. "Whether it's because of embarrassment, cultural norms, or a lack of understanding that vaginal discomfort can be tied to declining levels of estrogen, too many women are waiting a year, or two or three, before they seek medical advice for their symptoms."[3]

      While it is obvious that vaginal discomfort may have a negative impact on the quality of one's sex life, research shows that women also felt vaginal discomfort had a negative impact on feeling healthy and attractive, exercise, travel, a loving relationship with a partner and overall quality of life.[2,3]

      "More than just 'ruining the mood,' vaginal discomfort can be debilitating for some women," says Dr. Minkin. "We hear stories in the office that women can't sit for too long, ride a bicycle, or wear pants because the discomfort is too great. It can really hinder a woman's lifestyle."

      "Our research shows that women don't feel comfortable discussing their vaginal symptoms with their health care professional or their partner, which further reinforces the taboo nature of this topic," said John Spera, Senior Director – Hormone Therapy Marketing, Novo Nordisk Inc. "We assembled this group of vibrant, outspoken menopause experts who can help encourage women to start the conversation and seek the help they need. GLAM™ (Great Life After Menopause) is not a campaign; it's a movement for empowerment and women's health, and it's long overdue."

      For more information about GLAM™ (Great Life After Menopause) and vaginal symptoms related to menopause, visit GreatLifeAfterMenopause.com.

      About GLAM™ (Great Life After Menopause)
      Five outspoken women's health advocates who have experienced menopause have united to lend their distinctive voices to help raise awareness of the vaginal changes associated with menopause; educate that these changes may be due to a chronic, treatable condition; and empower women to break the taboo and seek treatment so they can live their lives to the fullest. By harnessing the power of social media, the women of GLAM™ will rally women around this very important topic.

      The alliance members are:

      • Geri Brin, founder of women's online destination FabOverFifty.com
      • Ellen Dolgen, founder of Menopause Mondays, author of Shmirshky: The Pursuit of Hormone Happiness and owner of one of Healthline's 13 Best Menopause Blogs of 2013
      • Karen Giblin, founder of Red Hot Mamas, the largest menopause education program in North America. She is a sought-after speaker and influencer in the women's health care community and author of Eat to Defeat Menopause and Management Counseling for the Perimenopausal and Menopausal Patient
      • Barbara Hannah Grufferman, National Osteoporosis Foundation's first Bone Health Ambassador, AARP columnist and YouTube Channel host and author of The Best of Everything After 50: The Experts' Guide to Style, Sex, Health, Money, and More
      • Staness Jonekos, whose blog was also voted one of Healthline's 13 Best Menopause Blogs of 2013, is also a contributor to the Huffington Post and Dr. Oz's Sharecare.com. She has appeared on The Today Show and is a member of the North American Menopause Society

      Mary Jane Minkin, MD, FACOG, NCMP, clinical professor of obstetrics and gynecology at Yale University School of Medicine, will serve as the medical consultant to the alliance.

      GLAM™ (Great Life After Menopause) is assembled and sponsored by Novo Nordisk Inc.

      About Vaginal Atrophy
      Vaginal atrophy (VA) is the thinning and inflammation of the vaginal wall, which occurs when there is a reduction in levels of estrogens.[1] Estrogens, produced by the ovaries, are responsible for maintaining the structure and function of the vaginal wall, elasticity of the tissues around the vagina, and production of vaginal fluid.[1] Unlike certain other symptoms of menopause like hot flashes and night sweats, if left untreated, VA symptoms often get progressively worse over time. The symptoms are treatable; there are therapy options available that address the condition that causes them.

      For more information on vaginal changes related to menopause and different types of available treatment options, visit vaginaldiscomfort.com.

      About Novo Nordisk
      Headquartered in Denmark, Novo Nordisk is a global health care company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone-related disorders and women's health. For more information, visit novonordisk-us.com or follow our news in the US on Twitter: @NovoNordiskUS.

      © 2013  Novo Nordisk  All rights reserved.  0813-00017647-1  September 2013

      [1] The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3):357–369. 
      [2] Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying vaginal atrophy's impact on sex and relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners [published online ahead of print]. Menopause. 2013. doi:10.1097/GME.0b013e318295236f.
      [3] Nappi RE, Kokot-Kierepa M. Vaginal health: Insights, Views and Attitudes (VIVA) – results from an international survey. Climacteric. 2012;15:36-44.

      SOURCE Novo Nordisk

      Modal title

      Also from this source

      Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes

      Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes

      Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the...

      Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD

      Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD

      Novo Nordisk today announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg....

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Women

      Women

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.